Rigaku at 58.7x: The Five-Year Compound the Price Is Quietly Demanding

A P/E of 58.7 is not a label. It is a claim about the future, and the claim is specific enough to test. Start with what is on the page: FY2025 net income of 11.4 billion yen, adjusted earnings per share of 50.2 yen, and a price of 3,240 yen that sits roughly 23% above the 2,625 yen consensus average. At that price the market is not paying for the 11.4 billion yen it already has. It is paying for a number that does not exist yet, and the only honest way to argue with the price is to ask what that number has to be.

Here is the arithmetic. If you believe a fair forward multiple for an instruments-and-metrology business with a 55.79% gross margin and a 17.74% operating margin should settle somewhere around 25x earnings, generous but defensible for a durable franchise, then today’s price implies the earnings base has to more than double to grow into it. Net income climbing from 11.4 billion yen toward roughly 27 to 29 billion yen gets you a 25x multiple on the current 3,240 yen price. That is a compound of about 18 to 20% annually over five years, sustained, with no margin slippage along the way. The 58.7x is simply the present-tense expression of that five-year promise. The question is whether the operating figures that feed it can deliver the compound.

This is where the gross margin matters more than the headline. Margin improved by about 1.8 points year-on-year in the first half of FY2025, driven by pricing and product mix. That is the variable doing the heavy lifting in the bull arithmetic, because an 18% top-line compound that holds margin is a different animal from one that bleeds operating margin as the mix shifts toward lower-return semiconductor process-control hardware. Return on capital relative to cost of capital is what decides whether the reinvestment into metrology actually creates value or merely grows the asset base. The 1.8-point gain says pricing power was real recently. It does not say it survives five more years of scaling a capital-intensive equipment segment.

The capital-allocation signals point in opposite directions, and the multiple needs both to resolve favorably. The buyback of up to 4 billion yen, about 2.62% of shares, is a return-of-capital gesture. The 27% equity investment in Onto Innovation and the imec collaboration are reinvestment bets, the kind that consume cash and free cash flow before they produce any. A company cannot both compound at 18% organically and need to buy its way into the next process node. The honest test is FCF conversion: if operating income of 16.7 billion yen is converting cleanly into free cash flow, the reinvestment is funded from strength. If the alliances are draining the working capital cycle, the buyback is borrowing optimism the cash statement cannot yet underwrite.

The discount-rate environment is the quiet term in every one of these calculations. A 25x terminal multiple is only defensible if the rate you discount those distant earnings at stays low, and the regulatory layer around this business is not getting cheaper. Coordinated US, Japan, and Netherlands export restrictions on advanced semiconductor equipment to China sit directly on top of Rigaku’s process-control segment, raising compliance cost and the risk premium a careful buyer should attach to the semiconductor growth leg. The same restrictions that constrain one customer base are what redirect demand toward allied partners like Onto. Against that backdrop runs the steadier domestic pull: Japan’s aging population and policy push toward precision diagnostics keeps the analytical-instruments segment growing without the geopolitical overhang. Two engines, two very different risk premia, blended into one multiple.

Run the bull path cleanly and it does close. If revenue compounds at 18% for five years and the operating margin holds at 17.74%, the semiconductor metrology demand materializes, the Onto alliance converts into shipped units, and pricing offsets input costs, then earnings reach the high-20-billion-yen range and 58.7x today resolves into 25x tomorrow. The math works. It rests on two assumptions, and both are contestable. The first is that an 18% compound is achievable for a firm that just reported a Q1 profit and revenue decline. The second is that margin holds flat while the revenue mix tilts toward hardware that historically carries thinner returns than legacy analytical instruments. Break either one, a 14% compound instead of 18%, or a margin that erodes two points as the mix shifts, and the earnings base lands closer to 20 billion yen, which makes the fair price something nearer 2,600 than 3,240. That is the entire gap between the price and consensus, expressed as a margin-and-growth sensitivity.

History is unkind to multiples stretched this far on a forward promise. The pattern in equipment and component names that ran to similar premiums on a single secular thesis is consistent: the stock holds while each quarter confirms the compound, and it corrects sharply the first time the compound visibly slows, because at 58.7x there is no earnings cushion to absorb a miss. The same growth-multiple arithmetic showed up in Murata’s 67x earnings math after its 110% rally — a high multiple is only ever a forward claim, and the correction arrives when the claim and the quarterly print stop agreeing. Rigaku’s most recent print already showed profit falling. The price moved up anyway, which tells you the market is discounting the alliances and the buyback over the result in front of it.

One accounting detail sits underneath all of this and deserves a flag rather than a calculation. The reported operating margin, and therefore the P/E, is sensitive to how much development spend is capitalized onto the balance sheet versus expensed through the income statement. A higher capitalization rate flatters near-term margin and makes the 58.7x look more survivable than the underlying cash economics justify. I would not recompute the multiple on that basis, but I would not trust a margin that improves while R&D capitalization is rising either.

If net income compounds below 14% annually over the next two reporting years, or operating margin slips below 16% while the revenue mix shifts toward process-control hardware, the 18% path collapses and the price is discounting earnings that do not arrive. That is the number that breaks this. At 58.7x the burden of proof sits entirely on the compound, and a single business already reported the wrong direction last quarter.

Figures reflect the most recent available data and may differ slightly from live market prices. · © Mathstock